Frequency of EGFR Mutations in Non-small Cell Lung Cancer Patients: Screening Data from West Siberia |
Gervas, Polina
(Federal State Budgetary Scientific Institution "Tomsk Cancer Research Institute")
Ivanova, Anna (Federal State Budgetary Scientific Institution "Tomsk Cancer Research Institute") Vasiliev, Nikolay (Federal State Budgetary Scientific Institution "Tomsk Cancer Research Institute") Ananina, Olga (Federal State Budgetary Scientific Institution "Tomsk Cancer Research Institute") Zharkova, Olga (Regional Clinical Oncology Center) Rogovieva, Olga (Regional Clinical Oncology Center) Verzhbitskaya, Natalia (Regional Clinical Oncology Center) Didichuk, Ivan (Clinical Oncology Center) Cheremisina, Olga (Federal State Budgetary Scientific Institution "Tomsk Cancer Research Institute") Popova, Natalia (Federal State Budgetary Scientific Institution "Tomsk Cancer Research Institute") Goldberg, Victor (Federal State Budgetary Scientific Institution "Tomsk Cancer Research Institute") Cherdyntsev, Evgeny (National Research Tomsk Polytechnic University) Choynzonov, Evgeny (Federal State Budgetary Scientific Institution "Tomsk Cancer Research Institute") Cherdyntseva, Nadezda (Federal State Budgetary Scientific Institution "Tomsk Cancer Research Institute") |
1 | Ahmed ZA, Moatter T, Siddiqui A, et al (2014). Distribution of EGFR mutations commonly observed in primary lung adenocarcinomas in Pakistan as predictors for targeted therapy. Asian Pac J Cancer Prev, 15, 7125-8. DOI |
2 | Aisner DL, Marshall CB (2012). Molecular pathology of nonsmall cell lung cancer: a practical guide. Am J Clin Pathol, 138, 332-46. DOI ScienceOn |
3 | Cherdyntseva NV, Gervas PA, Litvyakov NV, et al (2010). Agerelated function of tumor suppressor gene TP53:contribution to cancer risk and progression. Exp Oncol, 32, 205-8. |
4 | Denisov EV, Litviakov NV, Zavyalova MV et al (2014). Intratumoral morphological heterogeneity of breast cancer: neoadjuvant chemotherapy efficiency and multidrug resistance gene expression. Sci Rep, 16, 4704-9. |
5 | Gridelli C, De Marinis F, Di Maio M, et al (2011). Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: implications for clinical practice and open issues. Lung Cancer, 72, 3-8. DOI |
6 | Imianitov EN (2008). Molecular diagnosis in oncology. Mol Biol, 42, 772-85. |
7 | Jemal A, Siegel R, Xu J, et al (2010). Cancer statistics, 2010. CA Cancer J Clin, 60, 277-300. DOI |
8 | Kalinkin DE, Karpov AB, Takhauov RM et al. (2014). Mortality from cancer of the population living close to a large nuclear power plant. Vopr Onkol, 60, 41-6 (in Russian). |
9 | Leidner RS, Fu P, Clifford B, et al (2009). Genetic abnormalities of the EGFR pathway in African American patients with non-small-cell lung cancer. J Clin Oncol, 33, 5620-6. |
10 | Liam CK, Leow HR, How SH, et al (2014). Epidermal growth factor receptor mutations in non- small cell lung cancers in a multiethnic Malaysian patient population. Asian Pac J Cancer Prev, 15, 321-6. DOI ScienceOn |
11 | Maemondo M, Inoue A, Kobayashi K, et al (2010). Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 25, 2380-8. |
12 | Mun SA, Larin SA, Brailovskii VV, et al (2006). Ambient air benz[a]pyrene and cancer morbidity in Kemerovo. Gig Sanit, 4, 28-30 (in Russian). |
13 | Ponomareva AA, Rykova EIu, Cherdyntseva NV et al. (2011). Molecular-genetic markers in lung cancer diagnostics. Mol Biol, 45, 203-17 ( in Russian). |
14 | Yang ZM, Ding XP, Pen L, et al (2014). Analysis of CEA expression and EGFR mutation status in non-small cell lung cancers. Asian Pac J Cancer Prev, 15, 3451-5. DOI |